Πηγαίνετε εκτός σύνδεσης με την εφαρμογή Player FM !
A Year in Review and a Look to the Future: BTKi in CLL and MCL
Manage episode 384873627 series 3256997
In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:
- SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
- TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
- ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
- BRUIN: Pirtobrutinib for Previously Treated MCL
- GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
- FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
- ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
- ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
- BRUIN: Pirtobrutinib for Previously Treated CLL
Presenters:
Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain
Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany
Link to full program:
https://bit.ly/3MNaUri
185 επεισόδια
Manage episode 384873627 series 3256997
In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:
- SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
- TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
- ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
- BRUIN: Pirtobrutinib for Previously Treated MCL
- GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
- FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
- ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
- ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
- BRUIN: Pirtobrutinib for Previously Treated CLL
Presenters:
Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain
Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany
Link to full program:
https://bit.ly/3MNaUri
185 επεισόδια
Alle Folgen
×Καλώς ήλθατε στο Player FM!
Το FM Player σαρώνει τον ιστό για podcasts υψηλής ποιότητας για να απολαύσετε αυτή τη στιγμή. Είναι η καλύτερη εφαρμογή podcast και λειτουργεί σε Android, iPhone και στον ιστό. Εγγραφή για συγχρονισμό συνδρομών σε όλες τις συσκευές.